Ashish Dhawan has marginally decreased his stake in Glenmark Pharma by 0.1%, yet maintains a significant investment of ₹727.2 crore, equating to a 1.8% stake. This action is considered a tactical rebalancing, possibly in response to market conditions or broader sector rotation, rather than a divestment from the pharma industry, which remains a core part of his holdings.